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Abstract
Background: Clostridium difficile infection (CDI) remains a major health problem worldwide. Antibiotic use, in
general, and clindamycin and ciprofloxacin, in particular, have been implicated in the pathogenesis of CDI. Here,
we hypothesized that antibiotics that are highly active in vitro against C. difficile are less frequently associated with
CDI than others. The primary goals of our study were to determine if antibiotic susceptibility and CDI are associated
and whether the antimicrobial susceptibility of C. difficile changed over the years.
Methods and results: We examined a large panel of C. difficile strains collected in 2006–2008 at the University
Hospital of Zurich. We found that the antimicrobial susceptibilities to amoxicillin/clavulanate, piperacillin/tazobactam,
meropenem, clindamycin, ciprofloxacin, ceftriaxone, metronidazole and vancomycin were similar to those reported in
the literature and that they are similar to those reported in other populations over the last two decades. Antibiotic
activity did not prevent CDI. For example, thre use of meropenem, which is highly active against all strains tested,
was a clear risk factor for CDI. Most of the antibiotics tested also showed a higher minimum inhibitory concentration
distribution than that of EUCAST. All strains were susceptible to metronidazole. One strain was resistant to vancomycin.
Conclusions: Antibiotic susceptibilities of the collection of C. difficile from the University Hospital of Zurich are similar
to those reported by others since the 1980. Patients treated with carbapenems and cephalosporins had the highest risk
of developing CDI irrespective of the antimicrobial activity of carbapenems.
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Background
Antibiotic-associated pseudomembranous colitis due to
toxin-producing clostridia was first recognized by Bartlett
et al. [1]. Today this manifestation is best known as
Clostridium difficile infection (CDI). CDI is the major
cause of nosocomial diarrhea. However, incidence rates
for community- vs. hospital-acquired CDI nowadays are
similar with 11.16 and 12.1 per 100,000 person years,
respectively [2].
C. difficile is a Gram-positive spore-forming anaerobic
rod that replicates exclusively in the lumen of the gastro-
intestinal (GI) tract. Disease manifestations are due to en-
terotoxin A, which affects barrier integrity, and cytotoxin
B, which induces cell death [3,4]. The clinical manifesta-
tions of CDI include mild-to-profuse diarrhea with
abdominal pain and, in the most severe form, toxic mega-
colon and perforation. The latter presentation has a mor-
tality rate of 25–40% [5]. The overall mortality rate of CDI
increased significantly since 2000 to approximately 6%
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today [6]. That increase is usually attributed to the emer-
gence of the ribotype 027 strain [6,7], but its cause is most
likely multifactorial [6]. Mutations in the ribotype 027
strain are thought to increase production of toxins A and
B [8]. A binary toxin is also produced [9-11]. Fatality rates
of CDI caused by strains with genes for the binary toxin
are twice those of CDI caused by strains that lack the
toxin. However, it is unknown if the binary toxin directly
contributes to the increased fatality rate or if it is an
epiphenomenon of strains with higher virulence [9].
The main risk factor for developing CDI is prior or
ongoing antibiotic use [12] that disrupts the flora of the
GI tract. C. difficile exists in a vegetative form or as a
spore. Disruption of the flora of the GI tract enables
C. difficile to sporulate and the vegetative forms to
proliferate, and if they contain the genetic information
for toxin formation, to induce CDI.
Various antibiotics have antimicrobial activity against
C. difficile. However, it is largely unknown whether the
inherent activity of those antibiotics protects against
CDI. In other words, some antibiotics with activity against
C. difficile (e.g., metronidazole) may prevent or delay
CDI despite disrupting the microbial flora [13,14]. Loss
of activity of fluoroquinolones against C. difficile and
the associated increase of CDI suggest that antibiotic
activity against C. difficile may, at least partially, hinder
proliferation and toxin production despite disrupting the
GI flora [15].
We hypothesized that antibiotics, which are highly active
in vitro against C. difficile, are less frequently associated
with CDI than others. Our primary goal was to determine
if antibiotic susceptibility and CDI are associated, and thus,
we determined the in vitro activity of antibiotics against C.
difficile recovered in 2006–2008 at a tertiary university
hospital. Furthermore, the minimum inhibitory concentra-
tions (MICs) were compared with published MICs and
the MIC distributions of EUCAST.
Methods
From September 2006 to June 2007 and from February
2008 to August 2008, all C. difficile strains cultured
from stool of patients with diarrhea were prospectively
collected in the laboratory of the Institute of Medical
Microbiology (IMM) at the University of Zurich. The first
specimens were collected to evaluate for the presence of
the ribotype 027 in Switzerland. The second set was used
to compare various assays. Patients were hospitalized or
seen on an outpatient basis at the University Hospital of
Zurich (USZ), a tertiary care hospital. There were no re-
peat stool specimens from patients with recurrent CDI.
The study was approved by the cantonal ethic committee
of Zurich, Department of Health (#EK-1561). The ethics
committee waived the need for informed consent from
the patients for this retrospective analysis.
Charts were reviewed retrospectively for 94 patients
who had a stool specimen positive for culture or toxin.
Clinical details were entered into a case report form gen-
erated in the database system Access (Microsoft Schweiz
GmbH, Wallisellen, Switzerland). The following data were
collected: demographics (e.g., sex, age and ethnicity), dur-
ation of hospitalization, ward, health state (e.g., previous
history, drug history with focus on anti-infective, gastric,
cytostatic and immunosuppressive medication, proce-
dures, such as surgery, tube feeding and their complica-
tions), and microbiological results as related to CDI.
“Underlying disease” was defined as the leading diagnosis,
and “complication” was defined as a disease engrafted on
the lead diagnosis (Additional file 1: Table S1). Because
antibiotic treatment may precede development of CDI for
up to 8 weeks [13], we recorded all antibiotics for this
time frame before collection of the stool specimen.
Isolation of C. difficile
Stool specimens were inoculated onto cycloserin-cefoxitin-
fructose agar (CCFA, Difco, Detroit, MI) plates that were
incubated under anaerobic conditions for at least 2 days at
37°C. Suspicious colonies were yellowish spreading col-
onies on CCFA (i.e., acid production from fructose) and
were confirmed by conventional methods (i.e., gas chro-
matography of metabolic fatty acids) and an agglutination
assay for the C. difficile somatic antigen (Microscreen
C. difficile latex confirmation assay, Lab M Limited,
Heywood, UK).
Detection of C. difficile toxin
C. difficile toxin testing was conducted in a cytotoxicity assay
[16]. Briefly, monolayers of human fibroblasts (MRC-5,
courtesy of W. Bossart, Institute of Medical Virology)
were maintained in tubes with 2 ml of 10% fetal calf serum
in Dulbecco’s minimal essential medium (DMEM, Gibco
Life Technologies, Zug, Switzerland) and inoculated with
200 μl of the supernatant of a centrifuged stool sus-
pension (diluted 1:10 in phosphate buffered saline, centri-
fuged for 10 minutes at 3000 g). After an overnight
incubation at 37°C, the monolayers were observed for
cytotoxic effects. In cases of positive cytotoxicity but
a negative culture for C. difficile, the specificity of the
cytotoxic effect by C. difficile cytotoxin was proved by a
neutralization assay. Briefly, supernatants (100 μl) of the
centrifuged stool suspensions were preincubated (30’,
room temperature) with an equal volume of C. sordellii
antitoxin (TechLab, Blacksburg, VA) that neutralizes
C. difficile cytotoxin and, in parallel, with phosphate buff-
ered saline, and both mixtures were retested in the cell-
culture cytotoxicity assay. Neutralization of the cytotoxic
effect by the antitoxin was considered confirmation of a
positive toxin result [16]. From September 2006 to June
2007, all isolates of C. difficile were frozen in skim milk
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and stored at −80°C. From February 2008 to August 2008,
isolates were kept in a chopped meat suspension and
stored at room temperature. C. difficile strains from pa-
tients with a negative cytotoxin assay were further charac-
terized by PCR. To detect the toxin genes tcdA and tcdB,
a crude DNA extract was obtained. Toxin genes were
detected in a multiplex PCR approach with the primers
TA1/TA2 and TB1/TB2 as described [17].
Antimicrobial susceptibility testing
Antibiotic susceptibility testing was done on subcultures
of the isolates of C. difficile on brucella sheep blood agar
(Difco) with the Etest (Biomérieux, Marcy-l’Etoile, France).
Plates were incubated for 48 h under anaerobic conditions
[18]. The Etest, based on predefined gradients of antibiotic
concentrations on a plastic strip, allowed us to determine
the exact MIC of anti-infective drugs. The following anti-
biotics were selected for susceptibility testing because
of their association with CDI: amoxicillin/clavulanate,
ceftriaxone, ciprofloxacin, clindamycin, meropenem, metro-
nidazole, piperacillin/tazobactam and vancomycin. The
MIC results were categorized in susceptible, intermediate
and resistant, following the guidelines of CLSI (Perform-
ance Standards for Antimicrobial Susceptibility Testing;
23rd Informational Supplement; http://www.clsi.org/) or,
if those were not available, with the values of EUCAST
(European Committee on Antimicrobial Susceptibility
Testing; http://www.eucast.org/).
Compilation of literature as related to antibiotic
susceptibility of C. difficile strains
We used “Clostridium difficile” and “susceptibility” as
key words to identify articles reporting data on antibiotic
susceptibility (MIC50, MIC90 or MIC distributions) of
C. difficile. We focused our literature research on papers
published between 1980 and 2013 since the focus of our
work was to get a most comprehensive idea about resist-
ance development over time and to compare our data
from Zurich to published data.
Statistical analysis
Statistical analyses used Stata/SE 13.1 (Stata, College
Station, TX). Odds ratios were calculated by comparing
the usage of antibiotics in relation to the duration from
admission to C. difficile–positive testing in the study
population to the overall usage of antibiotics at the USZ
in 2006–2008. Differences in the MICs between the
data from IMM and EUCAST were calculated using the
Wilcoxon rank-sum test and the non-parametric equality-
of-medians test. The Wilcoxon-rank-sum test determines
if the MICs from the two groups are from populations
with the same distribution, and the equality-of-medians
test tests the null hypothesis that the samples of the
two groups were drawn from populations with the
same median.
Results
Characteristics of the study population
The patient cohort (n = 94) was predominantly of Caucasian
origin (i.e., 84% Swiss, 12.8% from the European Commu-
nity, 1.1% from the U.S. and only 2.1% of Asian origin). Of
the patients, 82/94 (87.2%) were inpatients, and 34/92
(37%) underwent surgery. The most common underlying
diseases were malignancies and cardiovascular diseases
(Additional file 1: Table S1).
Diarrhea was explicitly documented in the charts in
81.9% of the cases. Hospital directives do not indicate
testing for C. difficile with no evidence of diarrhea. Thus,
most likely all patients included in this study suffered
from diarrhea even when documentation was missing.
Average duration of diarrhea was 6.8 days (median: 3 days).
In 46/94 (inpatients: 40, outpatients: 6) stool specimens,
C. difficile grew in the culture, and its toxin was detected
by the cell-culture cytotoxin assay directly from the stool
samples (Table 1). In 38/94 (inpatients: 33, outpatients: 5)
stool specimens, C. difficile grew, but the specimen was
negative in the cytotoxin assay. In 17 of those 38 cultures,
the toxin was detected at the DNA level by PCR. Also 10/
94 specimens (inpatients: 9, outpatients: 1) were culture
negative, but had a positive cytotoxin result confirmed by
the neutralization test. In five of those specimens with
negative culture, another specimen sample taken a couple
of days apart from the one analyzed for the C. difficile
toxin was available, which was then used for antibiotic
susceptibility testing.
Risk factors and clinical presentation
Many risk factors contribute to CDI [19]. Risk factors
were evaluated retrospectively before the first positive
culture of C. difficile (Additional file 1: Table S1). Inpa-
tients were hospitalized for 17.2 days in average (median
9 days). During their current hospitalization, 25 patients
(26.6%) were in the ICU for at least 1 day. Thirty patients
(32.6%) had one or more complications: 20 patients (21.7%)
suffered from infectious complications, and further
complications spanned the entire spectrum of medi-
cine (Additional file 1: Table S1). Seven patients (7.4%)
died shortly thereafter of causes unrelated to CDI.
In the 8 weeks preceding the first positive culture, 83.3%
of the patients (i.e., in- and outpatients) were prescribed
antimicrobials, 37.8% antifungal medication, 73.3% gastro-
intestinal medication, 37.8% immunosuppressive medica-
tion, and 20.0% cytostatic medication (Additional file 1:
Table S1).
Penicillins (i.e., amoxicillin, amoxicillin/clavulanate and
piperacillin/tazobactam) were the most commonly pre-
scribed antibiotics (i.e., 38.5% of our cohort took penicillins
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with an average duration of 4.6 days (median 4 days),
followed by cephalosporins (29.5%) and quinolones (26.9%)
with an average duration of 6.8 and 4.9 days, respectively
(median 6 and 2 days, respectively)) (Table 2). Further
antimicrobials were carbapenems (15.4%), glycopeptides
(10.3%), nitromidazoles (5.1%), lincosamides (2.6%), ami-
noglycosides (3.8%) and others (11.5%). Within the hospi-
talized patients, 25 were given one class of antibiotics
while 34 patients were given more than one class before
diagnosis of CDI (Additional file 2: Table S2).
Antibiotic susceptibility pattern of C. difficile
We observed a uniform susceptibility to metronidazole,
meropenem, and piperacillin/tazobactam, with one outlier
for vancomycin. The one outlier was a true vancomycin-
resistant strain or an erroneous MIC determination.
We believe that the observed resistance was a labora-
tory artifact. Unfortunately, the strain was lost. Over 90%
of all strains were susceptible to amoxicillin/clavulanate.
In contrast, more than 90% of the strains were intermedi-
ate or resistant to clindamycin, ceftriaxone and ciprofloxa-
cin (Table 3).
We wondered whether certain anti-infective drugs were
over-represented in our patient cohort and, thus, prefer-
entially associated with CDI. We compared the antimicro-
bial usage of our patient cohort to the overall usage of
antimicrobials in the USZ during the same period as de-
fined by daily dose/100 bed days. Carbapenems were given
considerably more often to the study population (Figure 1).
The numbers of prescriptions for glycopeptides and sul-
fonamides were about the same in those two groups. On
the other side, penicillins, fluoroquinolones, lincosamides,
aminoglycosides, and macrolides were prescribed signifi-
cantly less often than the cumulative usage of the hospital.
The MIC50 and 90 did not reveal a straightforward
increase over the last three decades (Additional file 3:
Table 1 Specimen collection available
Total number of patients n = 94
"Inpatients" n = 82 "Outpatients" n = 12
Clinical data sets Data complete of n = 78 Charts missing n = 4 Data complete
Stool analysis positive for toxin/culture; n = 94 +/+ −/+ +/−* +/+ −/+ +/+ −/+ +/−*
38 31 9 2 2 6 5 1
Antibiotic susceptibility testing done in n = 86 36** 31 4 2 2 6 4** 1
*a stool specimen taken a couple of days apart with growth of C. difficile was used for antibiotic susceptibility testing; an alternative stool specimens was only
available in 4/9 cases in the inpatient cohort.
**in two and one cases, respectively, from in- and outpatients, cultures were lost and no antimicrobial susceptibility testing could be done.
Table 2 Antimicrobial use during hospitalization and prior to detection of Clostridium difficile in stool
Antimicrobials Number of patients
(%) N = 78†
Duration of treatment Duration of treatment
Mean (+/− SD) Median (range)
All Antimicrobials 59 (75.6%) 10.8 (11.0) 7 (1–33)
Penicillins* 30 (38.5%) 4.6 (3.8) 4 (1–12)
Cephalosporins** 23 (29.5%) 6.8 (31.5) 6 (1–26)
Fluoroquinolones*** 21 (26.9%) 4.9 (6.6) 2 (1–12)
Carbapenems# 12 (15.4%) 9.8 (6.5) 4 (1–21)
Glycopeptides## 8 (10.3%) 5 (8.2) 2 (1–25)
Nitroimidazoles### 4 (5.1%) 5.8 (4.6) 5 (1–12)
Aminoglycosides†† 3 (3.8%) 2.7 (1.5) 3 (1–4)
Clindamycin 2 (2.7%) 4 (1.4) 4 (3–5)
Macrolides††† 1 (1.3%) 3 (0) 3 (3)
Trimethoprim/Sulfamethoxazole 9 (11.5%) 4.7 (5.0) 2 (1–14)
†4 charts of inpatients were missing.
The following antibiotics were recorded:
*Penicillins: amoxicillin (n = 2), amoxicillin/clavulanate (n = 13) acid, piperacillin/tazobactam (n = 18).
**Cephalosporins: cefazolin (n = 2), cefepime (n = 12), ceftazidime (n = 1), ceftriaxone (n = 3), cefuroxime (n = 5).
***Fluoroquinolones: ciprofloxacin (n = 19), levofloxacin (n = 1), norfloxacin (n = 1).
#Carbapenems: ertapenem (n = 3), imipenem/cilastatin (n = 2), meropenem (n = 8).
##Glycopeptides: teicoplanin (n = 2), vancomycin (n = 6); all glycopeptides were given intravenously.
###Nitroimidazoles: metronidazole (n = 3), ornidazole (n = 1).
††Aminogylcosides: garamycin (n = 1), tobramycin (n = 2).
†††Macrolides: azithromycin (n = 1).
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Table S3). A closer look, however, showed that the
MIC is subtly increasing for amoxicillin/clavulanate,
ceftriaxone, piperacillin/tazobactam and metronidazole.
The MICs we measured, among all MICs reported, were
always at the highest level. In the 1980s, ciprofloxacin and
clindamycin already showed a sharp increase in the
MIC50 and 90 [20-26].
MIC distribution of C. difficile to various antibiotics at the
University Hospital of Zurich is similar to data from EUCAST
We compared the MIC distribution of the isolates de-
scribed here with data from worldwide sources made
available by EUCAST (http://mic.eucast.org/Eucast2/).
The distributions of the epidemiological cut-off values
(ECOFF) showed significant differences between the
one obtained by the IMM and EUCAST (Figure 2) by
the Wilcoxon rank-sum test for amoxicillin/clavulanate
(p < 0.0001), clindamycin C p < 0.0001), ciprofloxacin
(p < 0.0027), metronidazole (p = 0.0003), piperacillin/
tazobactam (p < 0.00001) and vancomycin (p < 0.00001).
Similar results were obtained for the difference of the
medians of the two groups using the nonparametric
equality-of-medians test (amoxicillin/clavulanate, clin-
damycin C, piperacillin/tazobactam, ciprofloxacin and
Table 3 Antimicrobial Susceptibility of CDAD Isolates
Antimicrobials (n = 86) MIC interpretative criteria (μg/ml) (CLSI) Susceptible Intermediate Resistant
S I R
Amoxicillin/Clavulanate ≤4/2 8/4 ≥16/8 81 (94.2%) 1 (1.2%) 4 (4.7%)
Ceftriaxone ≤16 32 ≥64 3 (3.5%) 60 (65.1%) 33 (30.4%)
Ciprofloxacin@ ≤2 4 ≥8 0 1 (1.2%) 85 (98.8%)
Clindamycin ≤2 4 ≥8 7 (8.1%) 34 (39.5%) 45 (52.3%)
Meropenem ≤4 8 ≥16 86 (100%) 0 0
Metronidazole¶ ≤8 16 ≥32 86 (100%) 0 0
Piperacillin/Tazobactam ≤32 64 ≥128 86 (100%) 0 0
Vancomycin* ≤2 >2 85 (98.8%) 0 1 (1.2%)
@CLSI and EUCAST did not define breakpoints for ciprofloxacin. Here instead are the breakpoints given for moxifloxacin defined by CLSI which should closely
approximate the breakpoints of ciprofloxacin.
¶Breakpoints for metronidazole by EUCAST: S ≤ 2; R2 mg/L.
*No breakpoints defined by CLSI; breakpoints presented by EUCAST.
Figure 1 Patients treated with carbapenems or cephalosporins appear to have had a higher risk for developing CDI. Odds ratios were
calculated by comparing the intake of the various antibiotics examined in our study with the defined daily intake of the antibiotics prescribed in
the University Hospital of Zurich during the study period. The dashed line separates the antibiotics which are associated with a significant risk
for CDI.
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vancomycin, p < 0.0001; meropenem, p = 0.012; metro-
nidazole, p = .0.017).
Discussion
Here, we determined the antibiotics that are associated
with CDI in a tertiary hospital center in Switzerland and
whether the antibiotic susceptibility of C. difficile strains
influenced the occurrence of CDI. Our main findings are
that i) the antibiotics mostly associated with CDI are car-
bapenems and cephalosporins, ii) the preserved microbial
activity by some antibiotics to C. difficile does not prevent
CDI, and iii) antibiotic susceptibility showed a trend
to increases of the MIC50 and MIC90 of half of the tested
antibiotics for the strains collected at the USZ. Very im-
portantly, all C. difficile strains were susceptible to metro-
nidazole and vancomycin, except one vancomycin-resistant
strain that we believe was a laboratory artifact.
Patients with CDI had a wide variety of underlying dis-
eases (Additional file 1: Table S1). Neoplastic, cardiovas-
cular and gastrointestinal diseases were most common
Figure 2 MIC from the collection of C. difficile from ZH and from EUCAST. The white bars were the data from ZH, the black bars from
EUCAST. We compared the data from ZH with the data from EUCAST with the Wilcoxon rank-sum test and the nonparametric
equality-of-medians test.
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and probably reflect the frequency of hospitalization for
these conditions. We observed no accumulation in any
distinct division or ward, rendering highly unlikely that a
local outbreak contributed to the number of CDI cases.
We made a major effort to assess complications that
preceded the CDI. Infectious complications were by far
the most frequent and self-explanatory complication as a
trigger for CDI. All other complications occurred less
frequently and were equally distributed with each repre-
senting 1–7% of the total (Additional file 1: Table S1).
Fifteen patients suffered from CDI although they had
no antibiotic use in their history. These patients had a
number of risk factors: 12/15 had proton pump inhibitors,
and 7/15 suffered from malignancies treated with cyto-
static and/or immunosuppressive drugs. Only one patient
lacked identifiable risk factors. We know that proton
pump inhibitors, for example, represents an independent
risk factor for CDI [19]. Notably, 34/90 (37.8%) of patients
received antifungal drugs. Some studies have reported that
Candida in the GI-tract acts as protective factor against
CDI, and that the use of antifungals drugs is an independ-
ent risk factor for CDI [27,28]. We do not know the extent
to which antifungal drugs contributed to the CDI in our
cohort.
In our cohort, most cases of CDI occurred in patients
treated with penicillins, followed by patients treated with
cephalosporins, quinolones and carbapenems. However,
we must take into account the rank order of prescribing
the various antibiotics. Indeed, the defined daily dose/
100 bed days was the highest for penicillins, followed by
cephalosporins, quinolones and carbapenems (defined
daily dose/100 bed days (DDD/100bd) in 2006, 2007,
and 2008 for penicillins were 23.22, 25.77, and 26.10, for
cephalosporins were 9.36, 10.45 and 9.67, for quinolones
8.78, 9.82, 9.9, for carbapenems 3.66, 4.45 and 4.08,
respectively). Considering the rank order, we identified
the administration of carbapenems and cephalosporins as
a major risk factor for CDI in this cohort of patients.
Glycopeptides and sulfonamides are most likely also a risk
factor for CDI; however, the OR for these two antibiotic
classes was not statistically significant. In a paradoxical
finding, glycopeptides were identified as a potential trigger
for CDI. The reason is most likely its co-administration
with other broad-spectrum antibiotics and the fact that its
intravenous application has no therapeutic role against C.
difficile. Notably, in 9/11 cases where vancomycin was
prescribed, the patients received a combination of antibi-
otics. It remains unclear whether penicillins (i.e., amoxicil-
lin, amoxicillin/clavulanate and piperacillin/tazobactam)
due to their inherent activity against C. difficile, and the
aminoglycosides and macrolides due to their lack of activ-
ity against anaerobes are less likely associated with devel-
opment of CDI. Our data agree with a recently published
meta-analysis that reported the strongest association for
cephalosporins and clindamycin with CDI and a lesser
one for carbapenems, trimethoprim/sulphonamides, fluor-
oquinolones and penicillin combinations [29]. The differ-
ing results we observed for clindamycin, penicillins and
for fluoroquinolones are surprising – it might be due to
patient selection in the hospital or genetic differences in
the C. difficile strains but in fact remains enigmatic.
A major goal was to assess the local susceptibility pat-
terns of the strains isolated (Table 3) and to compare
them to patterns of strains worldwide and over the last
three decades (Additional file 3: Table S3). We observed
uniform susceptibility of C. difficile vis-à-vis merope-
nem, tazobactam/piperacillin, and metronidazole. Only
1/86 isolates was resistant to vancomycin with an MIC
measured of 6 μg/ml. This finding was striking since
vancomycin resistant isolates are a rarity worldwide. We
believe that this resistant strain is a laboratory artifact
i.e., erroneous MIC determination. In any case, the
reduced vancomycin activity would have no clinical
relevance: vancomycin at the doses given perorally or rec-
tally to treat CDI far exceeds the concentration of an MIC
of 6 μg/ml. Most isolates were susceptible to amoxicillin/
clavulanate. Note that EUCAST has defined MIC clinical
breakpoints solely for metronidazole and vancomycin, and
CLSI has them for most antibiotics but not for vanco-
mycin and ciprofloxacin. The C. difficile strains showed
mixed susceptibility to the other three antibiotics tested:
the predominant majority of isolates were of intermediate
susceptibility or resistant to ceftriaxone and clindamycin;
less than 10% were still susceptible. All isolates but one
was entirely resistant to ciprofloxacin.
Meropenem’ s antimicrobial activity against C. difficile
does not appear to protect against CDI; patients on mer-
openem suffered more frequently from CDI. This is
most likely due to the disruption of the GI flora and the
overall morbidity of patients requiring carbapenems or
co-medications, such as proton pump inhibitors. Very
positively, the nitromidazoles and glycopeptides were still
close to 100% active against C. difficile despite their fre-
quent use.
We compared the local susceptibility pattern to the
ECOFF (epidemiological cut-off value) data collection of
EUCAST "European Committee on Antimicrobial Sus-
ceptibility Testing (http://www.eucast.org). The ECOFF
aims to differentiate between wild-type and non-wild-
type strains (acquired resistance mutations), based on
MIC. Surprisingly, we found that the variance and the
median of the MIC from ZH differ from the MICs from
EUCAST. Overall, it appeared that the MIC for the anti-
biotics studied at ZH showed a shift to higher MIC apart
from ciprofloxacin and metronidazole. MIC for cipro-
floxacin was markedly higher for the data provided by
EUCAST than for the data in ZH even though all strains
in ZH were resistant. This difference in MIC might be
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related to ribotype 027, which is known for its par-
ticular high resistance to ciprofloxacin. We also ob-
served two populations of strains when looking at the
MIC for clindamycin and for amoxicillin/clavulanate.
EUCAST does not report this separation in two popula-
tions for amoxicillin/clavulanate. The differences noted
are most likely due to local prescription habits/directives;
indeed, at the University Hospital of Zurich, the directives
promote the use of amoxicillin/clavulanate and less of
ciprofloxacin whenever appropriate, in particular be-
cause of the progressive increase of ciprofloxacin resist-
ance of gram-negative bacteria.
The data collected by EUCAST, however, do not inte-
grate the MIC evolution over time. A compilation of the
literature since the first identification of C. difficile did
not reveal a substantial change of antimicrobial suscepti-
bility over time. In 1980, Dzink and Bartlett reported that
over 95% of all strains tested were susceptible to vanco-
mycin, penicillin G, ampicillin, and metronidazole, 60%
of the strains were susceptible to clindamycin, and all
strains were resistant to the cephalosporins tested
(i.e., cephalotin and cefoxitin) [24]. Thus, the discord
between the activities of penicillins and cephalosporins
was observed already in the very first report. Looking at
all data, there is tendency of increases in MIC for all
antibiotics tested over the last three decades, but a clear
picture is lacking (Additional file 3: Table S3).
Limitations of the study are the number of cases and
the retrospective nature of this work. The number of
cases we analyzed is in the range of cases presented in
published work; nonetheless, we acknowledge that inter-
pretations must be done cautiously due to the limited
number of cases and the changes in microbiological assays
over time. Our study was further limited by the lack of indi-
vidual treatment information for the control patients.
We therefore had to rely on hospital-wide prescribed
DDDs of the different antimicrobials as a comparison
group without information on which drugs were given
simultaneously. This and the limited sample size pre-
cluded multivariable analyses including all antimicrobials
which would have been preferable.
Conclusions
In summary, the antibiotic susceptibilities of the C. diffi-
cile samples from the University Hospital of Zurich are
similar to those reported by others. Patients treated with
carbapenems and cephalosporins had the highest risk of
developing CDI, irrespective of the antimicrobial activity
of carbapenems. Most likely, the underlying diseases or
complications, in concert with the carbapenems’ activity
on the GI-tract flora, rendered these patients more
susceptible to CDI. Differences of MICs between the data
from ZH vs EUCAST are minor and are most likely
due to local prescriptions habits. Very importantly, all
strains, but one, were fully susceptible to metronidazole
and vancomycin the antibiotic cornerstone for the treat-
ment of CDI.
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